Drugs / PMT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05632315 | Aug 2024 → Aug 2026 overdue | Enterococcus faecalis infection, Pseudomonas aeruginosa infectious disease, methicillin-resistant staphylococcus aureus infectious disease | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMT-001 | “Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)” NCT05632315 ↗ |
| Known as | PMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05632315 ↗ |
| Known as | PMT-002 | “Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)” NCT05632315 ↗ |
| Route | Rectal | “Fecal Microbiota for Transplant, enema product (PMT-001)” NCT05632315 ↗ |